IMV to Participate at Two Upcoming Investor Conferences
November 27 2019 - 7:05AM
Business Wire
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical-stage biopharmaceutical company pioneering a novel class
of immunotherapies, today announced that the IMV’s executive
management team will participate in two upcoming investor
conferences in December:
Piper Jaffray 31st Annual Healthcare Conference Date:
Wednesday, December 4, 2019 Presentation Time: 8:50 a.m. Eastern
Time Location: New York, NY
LD Micro 12th Annual Main Event Date: Wednesday, December
11, 2019 Presentation Time: 4:20 p.m. Eastern Time (1:20 p.m.
Pacific Time) Location: Los Angeles, CA
A live webcast of these presentations will be available under
“Events, Webcasts and Presentations” in the investors section of
IMV’s website and a replay will be available approximately one hour
after the presentation. Afterwards, it will be available for
approximately 30 days.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory approvals. IMV
Inc. assumes no responsibility to update forward-looking statements
in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, our ability to access capital, the successful and
timely completion of clinical trials, the receipt of all regulatory
approvals and other risks detailed from time to time in our ongoing
quarterly filings and annual information form Investors are
cautioned not to rely on these forward-looking statements and are
encouraged to read IMV’s continuous disclosure documents, including
its current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov/edgar.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform (DPX). This
patented technology leverages a novel mechanism of action that
enables the programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a single regimen in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect at
www.imv-inc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191127005128/en/
Investor Relations
Marc Jasmin, Senior Director, Investor Relations, IMV O:
(902) 492-1819 ext : 1042 M: (514) 617-9481 E:
mjasmin@imv-inc.com
Josh Rappaport, Director, Stern IR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media
Delphine Davan, Director, Communications, IMV M: (514)
968-1046 E: ddavan@imv-inc.com
IMV (NASDAQ:IMV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMV (NASDAQ:IMV)
Historical Stock Chart
From Apr 2023 to Apr 2024